Acetylcholinesterase (AChE; EC 3.1.1.7) is known to hydrolyze acetylcholine at cholinergic synapses. In mammalian erythrocyte, AChE exists as a dimer (G 2 ) and is proposed to play role in erythropoiesis. To reveal the regulation of AChE during differentiation of erythroblast, erythroblast-like cells (TF-1) were induced to differentiate by application of erythropoietin (EPO). The expression of AChE was increased in parallel to the stages of differentiation. Application of EPO in cultured TF-1 cells induced transcriptional activity of ACHE gene, as well as its protein product. This EPO-induced event was in parallel with erythrocytic proteins, for example, a-and b-globins. The EPO-induced AChE expression was mediated by phosphorylations of Akt and GATA-1; because the application of Akt kinase inhibitor blocked the gene activation. Erythroid transcription factor also known as GATA-1, a downstream transcription factor of EPO signaling, was proposed here to account for regulation of AChE in TF-1 cell. A binding sequence of GATA-1 was identified in ACHE gene promoter, which was further confirmed by chromatin immunoprecipitation (ChIP) assay. Over-expression of GATA-1 in TF-1 cultures induced AChE expression, as well as activity of ACHE promoter tagged with luciferase gene (pAChE-Luc). The deletion of GATA-1 sequence on the ACHE promoter, pAChE DGATA-1 -Luc, reduced the promoter activity during erythroblastic differentiation. On the contrary, the knock-down of AChE in TF-1 cultures could lead to a reduction in EPOinduced expression of erythrocytic proteins. These findings indicated specific regulation of AChE during maturation of erythroblast, which provided an insight into elucidating possible mechanisms in regulating erythropoiesis.
Acetylcholinesterase (AChE; EC 3.1.1.7) is an enzyme to hydrolyze acetylcholine at cholinergic synapses of vertebrates. By alternative splicing, a single gene encodes AChE that could generate different isoforms, that is, read-through form (AChE R ) as monomer, hydrophobic form (AChE H ) as dimer, and tailed form (AChE T ) as oligomer via association with proline-rich membrane anchor (PRiMA) or collagen Q (ColQ), mainly existing in the brain and muscle (Tsim et al. 1988; Massouli e et al. 1993; Xie et al. 2007) . AChE H is expressed as a glycophosphatidylinositol (GPI)-linked dimer (G 2 ), and anchored on plasma membrane of erythrocytes (Roberts and Rosenberry 1985; Bon et al. 1991) . Aside from this cholinergic function, emerging evidence suggests additional non-enzymatic functions of AChE in different tissues (Soreq and Seidman 2001; Xu et al. 2017) .
The differentiation of muscle and neuron causes an increase in AChE transcript (Tsim et al. 1992; Siow et al. 2002; Massouli e and Bon 2006) , and this transcriptional regulation is triggered by acetylcholine or other agents Jiang et al. 2003; Xie et al. 2007) . The regulation of different forms of AChE depends on spatial and temporal expression of AChE subunit, as well as the structural subunits, for example, ColQ and PRiMA. Among various DNA regulatory elements on ACHE gene, cAMP-responsive element, E-box, N-box and Elk motifs, located on ACHE promoter, have been shown to regulate the mRNA in muscle during the differentiation processes (Angus et al. 2001; Choi et al. 2001; Camp et al. 2008) . In parallel, a cAMP-dependent and a MAP kinase-dependent pathways have been proposed in regulating AChE expression during neuronal differentiation (Jiang et al. 2003; Camp et al. 2008; Liu et al. 2018) . The AChE 3 0 -untranslated region contains elements binding to RNA-binding proteins to regulate AChE expression, for example, HuD (Deschênes-Furry et al. 2003) , and PUM2 (Marrero et al. 2011) . HnRNP H is demonstrated to regulate alternative 3 0 splice site by binding to specific regions in exon 5a of human ACHE gene (Nazim et al. 2017) . Moreover, the stress-inducible cognitive impairments have been shown to play roles in induction of hippocampal microRNA-132, which consequently could suppress AChE expression (Shaltiel et al. 2013) . The microRNA-132-regulated AChE expression has been also revealed during inflammation (Mishra et al. 2017) . On the other hand, the regulation of AChE and its transcriptional activators in other non-neuronal cells were also reported, for example, osteoblast (Xu et al. 2016 (Xu et al. , 2017 .
In mammalian erythrocytes, the dimeric form of AChE is characterized by a hydrophobic C-terminus peptide having a GPI anchor (e.g. AChE H ). AChE was found in ER and Golgi apparatus of early erythroblasts, and showed restricted localization in Golgi apparatus at maturation (Soreq and Seidman 2001) . Similar to the brain enzyme, AChE exists as fully or partially glycosylated protein in the blood precursor cells (Luk et al. 2012) . The binding sites for hematopoietic transcription factors, for example, GATA-1, STAT5, LMO2 and RUNX1, are found in promoter region of human ACHE gene, which further supports the notion that AChE may be transcriptionally regulated in hematopoietic cells Deutsch et al. 2002) . In parallel, administration of anti-sense AChE in mice led to alteration in hematopoiesis (Lev-Lehman et al. 1994) , suggesting a precise regulation of AChE, as well as its possible function, in blood cell differentiation.
Erythropoietin (EPO), a glycoprotein majorly produced by kidney and liver (Eckardt et al. 1992; Koury et al. 2002) , regulates formation of red blood cell, that is, inducing erythropoiesis. Failure to increase amount of circulating blood EPO could lead to anemia (Babitt and Lin 2012) . During erythroblastic differentiation, the binding of EPO to its receptor triggers a series of gene activation, including erythroid transcriptional factors, for example, GATA-1 (Ferreira et al. 2005) . However, AChE has been known in erythrocyte for over 50 years, the regulation of which during erythroblastic differentiation unfortunately is not resolved. Here, an erythroblast-like cell line (TF-1) was employed to mimic the process of erythroblastic differentiation, and thus the regulation of AChE in this cell type could be determined.
Methods

Cell cultures and erythroblastic differentiation
The study was approved by the Hong Kong University of Science & Technology Animal and Plant Care Facility (Protocol number: 2016027-R1). TF-1 cells (CRL-2003; ATCC; Manassas, VA; RRID: CVCL_0559), an erythroleukemic cell line from human blood, were maintained at 37°C, 5% CO 2 in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin and 100 lg/mL streptomycin, 1 mM sodium pyruvate, 4.5 g/L glucose and 2 ng/mL GM-CSF (PHC2015). Prior to induction of differentiation, cells were kept in medium without GM-CSF overnight, followed by the addition of EPO (1 U/mL; PHC2054) on the next day. The TF-1 cell line is not listed in the database of commonly misidentified cell lines (International Cell Line Authentication Committee), and not authenticated by the authors. All culture reagents were from Life Technologies (Life Technologies, Carlsbad, CA, USA). The renewal of medium and EPO (1 U/mL) were done on alternative days, and the cell density was maintained at 4 9 10 5 cells/mL. Cell cultures were collected in high salt lysis buffer (10 mM HEPES, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 M NaCl and 0.5% Triton X-100), with the addition of the following protease inhibitors: 10 lg/mL leupeptin, 10 lg/mL aprotinin, 20 lM pepstatin, and 2.5 mM benzamidine HCl. The differentiated TF-1 cell was monitored by presence of hemoglobin content, stained with benzidine (0.4% w/v; Sigma, St Louis, MO, USA), identified under a microscope. Rat primary cultured osteoblasts were prepared and cultured by the method previously described (Xu et al. 2017) .
DNA construction and transfection
The cDNA encoding human AChE H was described previously (Siow et al. 2002; Luk et al. 2012) . The cDNA encoding human GATA-1 was acquired from DNASU Plasmid Repository (Tempe, AZ, USA). The DNAs corresponding to human AChE R , AChE H and AChE T plasmids were cloned into pcDNA4 plasmid vector (Bi et al. 2014) . The DNAs (~2.2 kb) encompassing human ACHE promoter, with or without GATA-1-binding site, were sub-cloned into pGL3 vector (BD Biosciences Clontech, Palo Alto, CA, USA) upstream of a firefly luciferase gene, designated as pAChE-Luc and pAChE DGATA-1 -Luc, respectively . Cultured TF-1 cells were transfected with cDNA constructs with TransIT X2 â Dynamic Delivery System (Mirus BIO, Madison, WI, USA), including pAChE-Luc, pGATA-1-Luc, pAChE DGATA-1 -Luc (Affymetrix, Santa Clara, CA, USA), GATA-1 cDNA, AChE cDNA, GATA-1 shRNA and AChE shRNA (Santa Cruz, Dallas, TX, USA). Transfection was performed 1 day after cells were plated. For every 5 9 10 6 cells in 1 mL medium, DNA: TransIT X2 â were mixed in the ratio of 1 : 2 (3 lg/6 lL) in antibiotic free medium and added to the cells within 20 min. Western blotting and protein phosphorylation For electrophoresis in denaturing but non-reducing conditions, the protein lysate was denatured at 100°C for 5 min in the presence of 2% sodium dodecyl sulfate (SDS). For reducing SDS-polyacrylamide gel electrophoresis (SDS-PAGE), the protein lysate was denatured in the presence of 2% SDS and 100 mM b-mercaptoethanol. The antibodies used were as follows: anti-AChE (at~76 kDa for reducing condition; 1 : 5000; Santa Cruz Biotechnology, Santa Cruz, CA, USA; RRID: AB_2289247), anti-GATA-1 (at~47 kDa; 1 : 2000; Santa Cruz Biotechnology; RRID: AB_2263157), anti-a-globin (~16 kDa; 1: 100 000; Santa Cruz Biotechnology; sc-21005), anti-b-globin (~16 kDa; 1: 100 000; Santa Cruz Biotechnology; sc-22718) and anti-GAPDH (at~38 kDa; 1: 100 000; Invitrogen, Carlsbad, CA, USA; RRID: AB_10977387) antibodies. For protein phosphorylation analysis, TF-1 cells were seeded in medium without GM-CSF, with or without treatment of 25 lM phosphatidylinositol 3 kinase inhibitor, LY294002 (Cell Signaling, Danvers, MA, USA; #9901), or 10 lM AChE inhibitor, BW284c51 (Sigma; A9013), followed by addition of EPO. The phosphorylations of Akt and GATA-1 were evaluated by immunoblotting with specific anti-phospho-Akt (~60 kDa; 1 : 5000; Cell Signaling; RRID: AB_329825), anti-phospho-GATA-1 (~43 kDa; 1 : 5000; Abcam Ltd., Cambridge, UK; sc-101687), anti-total Akt (~60 kDa; 1 : 10 000; Cell Signaling; RRID: AB_329827) and GATA-1 antibodies (~47 kDa; 1 : 10 000; Santa Cruz Biotechnology; RRID: AB_2263157). The immune complexes were visualized using the enhanced chemiluminescence method in strictly standardized conditions (Xie et al. 2010) . The intensities of bands were quantified by ImageJ2x analysis software (Rawak Software Inc., Dresden, Germany). The labeling intensities of the protein bands were in the non-saturating range of calibration curves.
Preparation of lipid-raft
The preparation of raft membrane fractions was carried out at 4°C, as described previously (Xie et al. 2010) . In brief, the cells were suspended in buffer A (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM benzamidine HCl, 10 lg/mL aprotinin, 10 lg/mL leupeptin), then sonicated at low intensity as to avoid heating. The preparation was centrifuged at 500 g/min to remove cell debris and nuclei. The resulted extract was centrifuged at 16 670 g for 30 min in a Sorvall TST 60.4 rotor (Du Pont Company, Wilmington, Delaware, USA). The resulting pellet was washed and re-suspended in buffer A containing 5% glycerol and 0.5% Triton X-100, as the total membrane fraction. The membrane fraction was subjected to a discontinuous flotation gradient, that is, 80% sucrose at the bottom, 30% sucrose in the middle layer and with 5% sucrose on the top. The discontinuous gradient was spun at 34 020 g in a Sorvall TST 60.4 rotor for 18 h at 4°C. Eleven fractions were collected from the top and used for various assays.
Chromatin immunoprecipitation assay TF-1 cells were gently fixed with formaldehyde and lysed by sonication to perform chromatin immunoprecipitation (ChIP) assay, using the Qiagen EpiTect ChIP OneDay Kit (Qiagen, Manchester, UK). The specific GATA-1-DNA complex was immuno-precipitated using anti-GATA-1 antibody (1 : 100; Santa Cruz Biotechnology; RRID: AB_2263157). The primers flanking the GATA-1-binding site of ACHE promoter (with reference to NC_000007.14 Homo sapiens chromosome 7; 5 0 at 100 894 483 nucleotide to 3 0 at 100 894 284 nucleotide), S: 5 0 -GCATTTGTCTGGATATGGGTGTC-3 0 and AS: 5 0 -GGTCGGTCGAGAAGCCAG-3 0 were used.
Sucrose-density gradient ultracentrifugation
The molecular forms of AChE was analysed by a continuous sucrose gradients (5-20%), created in a detergent-containing buffer (10 mM HEPES, pH 7.5, 1 mM EDTA, 1 mM EGTA, 0.2% Triton X-100, and 1 M NaCl). The gradient was prepared in 12-mL polyallomer ultra-centrifugation tubes. Samples of cell extracts (0.2 mL) containing equal amounts of protein were mixed with the sedimentation markers, ALP (6.1 S) and b-galactosidase (16 S), and loaded onto the gradients to be centrifuged at 246 940 g in a Beckman SW41 rotor at 4°C for 16 h. Approximately, 45 fractions were collected; AChE enzymatic activities were determined according to the method of Ellman, and the sedimentation values of the enzymes were calculated from the positions of markers (Chen et al. 2011) .
Other assays Protein concentrations were measured by the Bradford method with a kit from Bio-Rad (Hercules, CA, USA). Luciferase assay was performed by a commercial kit (Thermo Fisher Scientific, Waltham, MA, USA). In brief, cultures were lysed by a buffer containing 100 mM potassium phosphate buffer, pH at 7.8, 0.2% Triton X-100 and 1 mM dithiothreitol. Twenty lg of cell lysate was used for assay. The luminescent reaction was quantified in a GloMax â 96 Microplate
Luminometer (Promega Corporation, Madison, WI), and the activity was expressed as absorbance (up to 560 nm) per mg of protein.
Number of n indicates the biological replicates, which means different samples are measured across multiple conditions. Statistical tests were performed using one-way analysis of variance; differences from basal or control values were classified as * where p < 0.05, ** where p < 0.01, and *** where p < 0.001. No blinding and no randomization methods were employed in this study.
Pre-registration statement
This study was not pre-registered.
Results
EPO induces AChE expression in TF-1 cells
A human erythroblast cell line, named TF-1, was used here as a model system. This cell line is fully responsive to EPOinduced erythropoiesis and differentiates to late stage of matured erythroblast (Koury et al. 2002; Lui and Kong 2006) . By benzidine staining, the hemoglobin-containing TF-1 cells were identified. The differentiated cells, induced by EPO application, were stained with blue color (Fig. 1a) . TF-1 cells responded to challenge of EPO in a sigmoid curve manner. The maximal induction of differentiation was at 5 U/mL EPO, which showed~70% cells being stained, that is, differentiated erythroblast (Fig. 1a ). An increase in EPO dosage to 10 U/mL did not increase further the stained cells: the ED 50 of EPO induction was at~0.5 U/mL. TF-1 cells expressed a low level of AChE before differentiation, which was up-regulated by EPO application in a time-dependent manner. In EPO-induced differentiation of TF-1 cells, the level of AChE protein (at~70 kDa and 76 kDa) was increased in a time-dependent manner (Fig. 1b) . The maximal induction was at 8-10 days of EPO challenge (Fig. 1b) . Serving as controls, the expression of erythrocytic proteins, a-globin, b-globin (both at 16 kDa) and GATA-1 protein (~48 kDa), were markedly increased after application of EPO in cultures; the induction was similar to the profile of AChE expression during differentiation (Fig. 1b) . In all cases, the protein amounts were at plateau after 8 days of treatment. In non-reducing gel electrophoresis, the dimeric form of AChE (~150 kDa) was shown to be the only form being induced by EPO-treatment (Fig. 1c) . After 8 days of EPO treatment, AChE activity was increased by~5 folds, reaching the plateau (Fig. 2a) . To confer the identity of AChE, the cell lysate of TF-1 cells, with or without EPO treatment as well as human erythrocyte lysate as a positive control, were subjected to sucrose density gradient analysis. AChE activities at~6 S were revealed (Fig. 2b) , which closely resembled the sedimentation index of the G 2 form enzyme in erythrocyte (Massouli e et al. 1993; Luk et al. 2012) .
To determine AChE isoform in TF-1 cells, a method of real-time PCR coupled with standard curves in measuring absolute amount of AChE transcript was used (Bi et al. 2014) . Before EPO application in TF-1 cells, the mRNA copies of AChE H , AChE T and AChE R per lg of total RNA were 2.7 9 10 5 , 0.67 9 10 5 and 8.9 9 10 3 , respectively (Fig. 2c ). The copies of AChE H mRNA increased gradually to~10 9 10 5 copies on day 8 and leveled off afterwards. In contrast, the mRNA copies of AChE T and AChE R remained at low level during the differentiation (Fig. 2c) . Thus, the enzymatic activity in TF-1 cells was triggered mainly by AChE H form, the G 2 form. Human ACHE promoter tagged downstream with a luciferase (i.e. pAChE-Luc) was transfected into TF-1 cells and then subjected to EPO challenge.
The application of EPO induced pAChE-Luc activity was in a dose-dependent manner: a maximal induction of~10 folds was revealed at~5 U/mL EPO (Fig. 2d) . In parallel, the promoter of GATA-1 tagged with luciferase (i.e. pGATA-1-Luc) being transfected in TF-1 cells was markedly induced by EPO application, serving as a control here (Fig. 2e) . The profiles of EPO-induced promoter activities in both AChE and GATA-1 were rather similar. The GPI-linked G 2 dimeric AChE is expected to be localized in lipid-raft. The protein lysate of TF-1 cells, differentiated or undifferentiated, was subjected to lipid-raft separation. The EPO-induced AChE activity in TF-1 cells was revealed to be mainly raft-associated (Fig. 3a) . ALP and Na + /K + -ATPase served as controls showing the specific localization in the raft, as revealed by ALP activity and western blotting (Fig. 3a and b) . The raft-associated AChE and EPO receptor proteins were markedly increased after EPO treatment (Fig. 3b) .
EPO-induced AChE expression is mediated by Akt
The phosphorylations of Akt and GATA-1 are the downstream signaling of EPO activation. The roles of Akt and GATA-1 in EPO-induced AChE expression were tested in cultures. In cultured TF-1 cells, no phosphorylated Akt and GATA-1 were detected in the undifferentiated cells, and application of EPO markedly induced Akt and GATA-1 phosphorylations (Fig. 4a) . Addition of LY294002, an inhibitor of Akt, blocked all EPO-induced Akt and GATA-1 phosphorylations (Fig. 4a) . The application of BW284c51, an AChE inhibitor, did not show any effect on the phosphorylation, suggesting AChE enzymatic activity should not play any role in this signaling (Fig. 4a) .
The Akt inhibitor was tested in cultures as to reveal the possible role of Akt in EPO-induced AChE expression. In TF-1 cultures with or without EPO challenge, application of LY294002 abolished at least 40% of AChE activity and protein (Fig. 4b ). An AChE inhibitor (BW284c51) did not change AChE protein level (Fig. 4b) : this inhibition did not affect the EPO-induced AChE protein (Fig. 4b) . As controls, a-globin (Fig. 4c) and b-globin (Fig. 4d) were affected by LY294002 but not by BW284c51. As a summary here, the EPO-induced AChE was partially mediated by Akt and GATA-1 signaling.
GATA-1 regulates AChE expression
Human ACHE promoter has a GATA-1-binding site at À107 to À104 , which is conserved in human, mouse and rat (Fig. 5a ). The role of GATA-1, a crucial transcription factor in regulating hemoglobin synthesis, in EPO-induced AChE expression was hypothesized here. A ChIP assay was used to show a direct binding of GATA-1 transcription factor to the ACHE gene in TF-1 cell lysate. Without EPO treatment, the GATA-1 occupancy at ACHE gene was detected, accounting~4 folds of enrichment as that of control (Fig. 5b) . The EPO treatment increased the precipitated ACHE gene by~8 folds of enrichment. The gene encoding GAPDH, served as a control, was not precipitated. These results provided a direct evidence that AChE in erythroid cells could be regulated transcriptionally by GATA-1, supporting the enhanced EPO-induced AChE expression in TF-1 cells.
To further support this notion, GATA-1 cDNA was being transfected into cultured TF-1 cells, which brought~40% increase in protein level for itself (Fig. 6a) . In contrast, the knock-down of GATA-1, by shGATA-1 transfection, reduced the protein by~50%. These results showed the successful transfection in cultures. The amount of AChE, both activity and protein, was induced in GATA-1 overexpressed cells, and which was significantly decreased in GATA-1 knock-down cells (Fig. 6a) . Depending on GATA-1 expression, the responsiveness of cells, in terms of AChE induction, to EPO challenge was altered (Fig. 6a) . In pAChE-Luc transfected TF-1 cells, the knock-down of GATA-1 did not brought significant changes in pAChE-Luc transcriptional activity. In contrast, the over-expression of GATA-1 increased the promoter activity by~50% (Fig. 6b) . In parallel, the sensitivity to EPO challenge was markedly increased in GATA-1 over-expressed TF-1 cells, and which was decreased in GATA-1 knock-down cells (Fig. 6b) . Serving as controls, the regulations of a-globin (Fig. 6c) and b-globin (Fig. 6d ) in cultured TF-1 cells were depending on amount of GATA-1 in responding to EPO, that is, similar to that of AChE induction.
The direct role of GATA-1 site of ACHE promoter was further illustrated. A mutated promoter construct, pAChE DGATA-1 -Luc, having a mutation on GATA-1-binding site of ACHE promoter (Fig. 7a) , was used in transfected TF-1 cells. As revealed by ChIP using anti-GATA-1 antibody, GATA-1 showed no binding to the mutant pAChE DGATA-1 -Luc when compared to that of pAChE-Luc (Fig. 7b) . Serving as a control, GAPDH was not precipitated by the anti-GATA-1 antibody. In the transfected cells, application of EPO did not show any induction on pAChE DGATA-1 -Luc activity, even by different days or different doses (Fig. 7c) . Being a control, the activity of pAChE-Luc was activated robustly in responding to challenge of EPO in time-and dose-dependent manners (Fig. 7c) . The mutated construct pAChE DGATA-1 -Luc was not affected in other cell line (e.g. osteoblast) during differentiation (Fig. 7c) , as reported previously (Xu et al. 2017), suggesting its specificity in erythroblastic cell. The GATA-1 cDNA was used here in transfected TF-1 cells to increase the amount of GATA-1. The over-expression of GATA-1, when co-expressed with pAChE-Luc, induced the promoter activity by~3 folds, and as expected the mutant promoter, pAChE DGATA-1 -Luc, did not show any response to over-expression of GATA-1 (Fig. 7d) . As a control, the expression of a-globin was markedly induced by GATA-1 over-expression in both cases of transfection (Fig. 7d) .
Role of AChE in EPO signaling
The possible role of AChE in EPO signaling was tested here in cultured TF-1 cells. The expression of AChE was manipulated by means of over-expression or knock-down by transfection of AChE cDNA or shRNA. In differentiated and undifferentiated cells, the over-expression of AChE brought an elevation of enzymatic activity at~6S, while the knock-down of AChE reduced the peak activity by half (Fig. 8a) . As expected, the expressions of AChE protein were depending on transfection of AChE constructs ( Fig. 8b) : these results served as the first requirement to perform the below analysis. The downstream signaling of EPO receptor was analyzed in transfected TF-1 cells. By AChE shRNA or cDNA transfection, the amount of AChE activity was altered in pGATA-1-Luc expressing cells (Fig. 8c left panel) . The EPO-induced pGATA-1-Luc activity was decreased in AChE knock-down cells; while the activity was increased in AChE over-expressed cells (Fig. 8c  right panel) . The activation of GATA-1 by phosphorylation was also determined here. The EPO-induced GATA-1 phosphorylation was changed in parallel to amount of AChE being expressed by TF-1 cells, as introduced by transfection, that is, increased phosphorylation in AChE over-expressed cells (Fig. 8d ). Serving as a control, the expression of globin mRNAs was determined. Application of EPO to cultured TF-1 cells increased the levels of transcript and protein corresponding to a-globin and b-globin by~50% ( Fig. 8e  and f) . The knock-down AChE in TF-1 cells reduced the EPO-induced globin expression, while the over-expressed AChE cells showed higher response to EPO challenge ( Fig. 8e and f) . Thus, the existence of dimeric AChE in TF-1 cells could modulate the EPO-induced signaling, as well as the expression of erythroid proteins.
Discussion
Apart from nervous system, AChE is found in other tissues and cells, for example, bone, liver, spleen, kidney, pancreas, heart, intestine, sperm, lymphocyte and erythrocyte (Jbilo et al. 1994; Genever et al. 1999; Mor et al. 2008; Xu et al. 2016 Xu et al. , 2017 . The non-cholinergic functions of AChE have been proposed in development of aforementioned tissues/ cells. For example in mammals, AChE is proposed to involve in osteoblastic differentiation (Inkson et al. 2004; Xu et al. 2017) , to enhance sperm motility (Mor et al. 2008) and to play role in cell cycle arrest of intestinal cell (Xiang et al. 2008) . Several lines of recent evidence support the role of AChE in erythropoiesis. In erythroblasts, AChE was found to be regulated for its synthesis in ER and Golgi apparatus (Soreq and Seidman 2001) . In parallel, hemoglobin synthesis was impaired during AChE inhibition with anti-cholinesterase inhibitors, as well as reduction in erythroid population, suggesting a defect in erythropoiesis (Barr and Koekebakker 1990) . In vivo administration of antisense of AChE led to alterations in hematopoiesis in mice (Lev-Lehman et al. 1994; Gilboa-Geffen et al. 2012) . On the other hand, a peptide derived from stress-associated AChE (e.g. AChE R ) was shown to regulate proliferation of hematopoietic progenitor cells (Deutsch et al. 2002) . Interestingly, an increase in erythrocyte AChE activity was detected among patients suffering from polycythemia vera, a myeloproliferative blood cancer in which bone marrow makes too many red blood cells (Da z browski et al. 2011). These findings suggest that in hematopoietic cells, AChE is expressed in a cell-lineage specific manner, and which may have a possible role in regulating erythroid growth and differentiation. TF-1 cell was chosen to be an erythroblast cell model for this study. Before differentiation, TF-1 cell is corresponding to early erythroblast (pro-erythroblast). After EPO exposure, TF-1 cells differentiate into late stage erythroblast and halted before enucleation (Koury et al. 2002; Lui and Kong 2006) . TF-1 cell expresses a basal level of G 2 dimeric AChE, resembling erythrocyte AChE. Moreover, TF-1 cell does not express PRiMA and ColQ. In determining absolute number of AChE transcripts in EPO-induced TF-1 cell, AChE H was found to be the dominant form, which was much higher than that of AChE R and AChE T variants. AChE H naturally comes with GPI-anchor right after synthesis, the dimeric form of AChE should be the only form of AChE targeting to plasma membrane in erythroblast and erythrocyte. Inversely, AChE R (1 U/mL). The ChIP assay was performed. Two specific primers, shown as arrows in (a), for amplification of the GATA-1-binding sitecontaining fragment on human ACHE promoter were used (pACHE). Agarose gel showed the size of PCR product at~200 bp. The PCR primers for gene encoding GAPDH served as negative control. The input (DNA fragment included for ChIP), blank (no input) and genomic (DNA of ACHE promoter) served as control. Values are expressed as fold-increase to basal reading, and are in means AE SEM., n = 4 (number of samples). **p < 0.01. and AChE T were shown to be two predominant transcripts being increased in differentiated murine erythroleukemia; while extremely low level of AChE H was being detected. The increase in AChE transcripts was proposed to be an outcome of the stabilization of transcripts (Chan et al. 1998; .
Among the blood cell lineages, AChE is known to be present on erythrocyte, thrombocyte, macrophage and T-cell. While AChE activity is shown to be absent in their precursor cells or even further upstream in the common myeloid/ lymphoid progenitors. An immature megakaryocyte, a precursor of thrombocyte, was found to be devoid of AChE expression (Matsumura-Takeda et al. 2007) , where administration of IL-11 led to megakaryocyte differentiation with an increase in AChE expression. In another study, the transcriptional expression of AChE, as well as AChE mRNA splicing, was down-regulated during differentiation of megakaryoblasts (Grisaru et al. 1999) . By utilizing transgenic mice over-expressing human AChE R , the potential role of AChE R in thrombopoietic recovery was proposed (Pick et al. 2006) . In lymphoid lineage, T-cells are characterized by AChE expression; while B-cells do not (Szel enyi et al. 1982) . Thus, AChE variants might play specific roles in different cell types. These lines of evidence illustrated that AChE should not be as simple as a cell surface marker, which might participate in the blood lineage progression.
The possible functions of erythrocytic AChE have been put forward by Soreq's group. The regulatory role of AChE in differentiation of hematopoietic stem cells was illustrated (Gilboa-Geffen et al. 2012) . Inhibition of AChE activity did not cause anemia, while AChE was actively synthesized in erythroblasts (Keyhani and Maigne 1981) . This suggested that the presence of AChE could be important in erythropoiesis. This notion is further supported by several lines of evidence, which include: (i) ACHE-/-mice suffering normocytic anemia in our preliminary study (Xu ML, Luk WKW, Liu EYL, Wu KQY, Yao P, Dong TTX and Tsim KWK, unpublished result); (ii) EPO inducing AChE expression via the transcription factor GATA-1; and (iii) AChE amount modulating EPO-mediated downstream gene expressions. In parallel, a transient knock-down of ACHE gene could lead to reduction in erythroid and lymphocyte colonies in bone marrow, as reported by Lev-Lehman et al. (1994) .
Erythroblasts, having the highest amounts of EPO receptor, are differentiated in the presence of EPO and elevated expression of erythroid transcriptional factors, for example, Fig. 8 The erythropoietin (EPO)-induced signaling is altered by expression of AChE in cultured TF-1 cells. (a) TF-1 cells were transfected with mock control (non-sense shRNA), or cDNA encoding AChE H or AChE shRNA (shAChE), followed with or without EPO treatment of 1 U/mL for 2 days. The cell lysates were subjected to sucrose density gradient analysis. AChE activity were expressed in arbitrary units. (b) Upper panel: protein lysates from (a) were subjected to western bloting with anti-AChE and anti-GAPDH antibodies. Lower panel: quantitation of AChE protein, calibrated from the blots by densitometry. (c) TF-1 cells were transfected as in (a) together with pGATA-1-Luc, followed with or without EPO treatment of 1 U/mL for 2 days. AChE activity was determined to confirm the transfection (left panel). The cell lysates were assayed for luciferase activity (right panel). (d) TF-1 cells were transfected as in (a), and then growth factorstarved for at least 16 h, followed with 5 U/mL EPO challenge for 60 min. Starved TF-1 cells without EPO challenge served as control. The cell lysates were analyzed by Western blotting. The total and phosphorylated GATA-1 (P-GATA-1) were revealed, using specific antibodies (upper panel). Lower panel: the quantitation from the blots was shown by a densitometer. (e) TF-1 cells were treated as in (c). The a-globin mRNA was revealed by real-time PCR (left panel). The protein lysates were subjected to western bloting with anti-a-globin antibody. The lower right panel shows quantitation of a-globin protein, calibrated from the blots by densitometry. (f) Similar to (e) for b-globin analysis. Values are expressed as fold-increase to basal reading, and are in means AE SEM., n = 4 (number of samples), each with triplicate samples, *p < 0.05; **p < 0.01; ***p < 0.001.
GATA-1, FOG-1 and EKLF. Here, we proposed that AChE could be another inducible protein during the EPO signaling in erythroblast. In addition to blood cells, EPO and EPO receptor have been found in non-hematopoietic tissues, such as neural tissues, whose expressions are regulated temporally and spatially during brain development and injury (Yu et al. 2002; Marti 2004; Tsai et al. 2006) . Under hypoxia, EPO, produced in the brain, provides specific protection by increasing oxygen level in the brain, and therefore maintains neuron survival. Moreover, the EPO-mediated neuroprotection during injury requires the activation of JAK2, STAT5, Akt and MAPK signaling pathway (Ma et al. 2014) . In parallel, the expression of EPO receptor in developing brain appears in regions associated with neurogenesis (Marti 2004; Tsai et al. 2006) . To further support the neurogenic role of EPO, the EPO receptor-depleted mice exhibited increased apoptosis in the brain as early as at day E10.5 (Yu et al. 2002) . In erythroid cell during erythropoiesis, GATA-1, a downstream component of EPO-induced phosphatidylinositol 3 kinase/Akt signaling, shares a common consensus-binding sequence of WGA TAR (in which W indicates A/T and R indicates A/G), which are related by a high degree of amino acid sequence identity within their zinc finger DNA-binding domains. In contrast to erythroid cells, GATA-3, instead of GATA-1, is a requisite transcription factor being induced by EPO during brain development (Zhao et al. 2008) . The possible regulation of EPO-induced AChE expression in neurons therefore could be an interesting question here.
